Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
Michel Azizi, Jenifer Michelle Brown, Jamie P. Dwyer, John M Flack et autres
BACKGROUND: Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension. METHODS: The Bax24 international, phase 3, randomised, …
fr, us, Afrique du Sud, pl, es, se, au, jp, cn, gb (code pays fourni par la source)
25 citations
The Lancet